Roche launches subcutaneous lung cancer immunotherapy, cuts delivery time to 7 min
Pharma major Roche on Thursday announced the launch of the immunotherapy drug Tecentriq that can, for the first time, be administered subcutaneously, reducing drug delivery time to seven minutes compared to conventional intravenous infusions, which take at least a couple of hours. Roche introduced subcutaneous Tecentriq in India, a breakthrough immunotherapy that cuts cancer treatment time by 80%. (iStock/ Representative photo) “By reducing treatment administration time to approximately seven minutes, Tecentriq SC is a breakthrough innovation that has the potential to dramatically improve the cancer treatment experience of patients — reducing treatment time by 80%,” Roche India said in a statement. Lung cancer is one of the most common cancers in India, with about 80,000 cases diagnosed annually. Doctors say immunotherapy has been a game changer in cancer treatment, and a drug that can be delivered subcutaneously makes treatment more comfortable for cancer patients. “We have been using the drug in our hospital for some time. It has proved to be a great mental relief for patients. Also, cancer patients can be so frail at …





